Clinical Trial

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

Study acronym: SGLT2i in CRS
Completed Phase 2
View on ClinicalTrials.gov →
Summary
The long-term objective of this study is to test whether the addition of SGLT2 inhibitors to usual care during acute heart failure management in patients who develop kidney injury shortens the time to achieving symptomatic improvement and kidney function recovery. The study aims to assess feasibility and acceptability of such a randomized clinical trial.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-14
notable Primary completion moved earlier: 2026-05 -> 2025-09-25 2026-08-14
minor Completion moved earlier: 2026-05 -> 2025-12-25 2026-08-14
Trial Details
NCT Number NCT06111768
Lead Sponsor Yale University
Collaborators: American Heart Association
Conditions Cardiorenal Syndrome
Enrollment 30 participants
Start Date 2024-05-30
Primary Completion 2025-09-25 (estimated)
Study Completion 2025-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-13